REG - Oxford Nanopore Tech - Oxford Nanopore strengthens executive team

Oxford Nanopore TechnologiesAnnouncement

21/05/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260521:nRSU2489Fa&default-theme=true

RNS Number : 2489F  Oxford Nanopore Technologies plc  21 May 2026

Oxford Nanopore Technologies plc

 ("Oxford Nanopore" or the "Company") 

Oxford Nanopore strengthens executive leadership team

Appointment of first Chief Medical Officer and Chief Information Officer

 

21 May 2026

Oxford Nanopore Technologies plc (LSE: ONT), the company delivering a new
generation of nanopore based molecular sensing, today announces the
appointments of Davide Manissero MD as Chief Medical Officer and Andrew Watson
as Chief Information Officer. Together, these roles strengthen the Company's
leadership as it expands into clinical and regulated markets while scaling its
data, software and machine learning capabilities.

As Oxford Nanopore's first Chief Medical Officer (CMO), Davide will lead the
Company's global clinical strategy leveraging his considerable experience
across regulated clinical environments. Davide joins from
Radiometer (a Danaher company), where he is currently CMO. He previously
served as CMO at QIAGEN, leading global medical and clinical affairs, and held
roles at ECDC and the WHO focused on infectious diseases and public
health.

Andrew Watson will lead the Company's information systems, data, digital
transformation, machine learning, and product software development. He will
focus on scaling the Company's digital and customer-facing platforms,
improving user experience, and embedding machine learning across its
technology and product development. Andrew joins from Mimecast, where he leads
AI and threat protection engineering. He has previously held senior roles at
Healx and Dyson, where he established machine learning and biomedical
research teams.

Francis Van Parys, Chief Executive Officer, of Oxford
Nanopore, commented:

"Oxford Nanopore has built a strong track record of innovation, and we are
now building on that with focus on execution and scaling. Davide and Andrew
bring deep expertise in clinical development, data and machine learning,
strengthening our ability to scale our business and translate our technology
into real-world impact in research and healthcare."

Davide Manissero, MD, added:

"What drew me to Oxford Nanopore is the ability to generate rich biological
information, rapidly, and the potential to bring this benefit
to traditional and broader care settings. That opens up possibilities
you don't see with many existing technologies. The opportunity now is to
focus on where this can genuinely enhance clinical decisions and patient
outcomes. I'm looking forward to working with our teams, customers and
partners to help deliver on this promise."

Andrew Watson, said:

"Oxford Nanopore's technology sits at the intersection of biology, data, and
advanced computing, creating a powerful platform for innovation. I am excited
to help scale the Company's digital and software capabilities, harness machine
learning across the company and product portfolio, and deliver seamless,
high-performance user experiences that enable customers to extract maximum
value from their data as adoption continues to grow." 

Andrew Watson and Davide Manissero join the Company on 15 June and 3
August respectively. Their appointments follow the announcement that Tina St
Leger will join Oxford Nanopore as Chief People Officer in June 2026.
Davide, Andrew and Tina will join the Executive team.    

Changes to Director Roles and Responsibilities 

In accordance with UK Listing Rule 6.4.6(3), the Company notes
that responsibility for the commercial function will transfer from
Nick Keher, CFO, to Francis Van Parys, CEO, effective 1 July 2026. 

-ENDS-

 

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:     ir@nanoporetech.com (mailto:ir@nanoporetech.com)

Media:         media@nanoporetech.com (mailto:media@nanoporetech.com)

 

Teneo (communications adviser to the Company)

Tom Murray and Lisa Jarrett-Kerr

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com
(mailto:OxfordNanoporeTechnologies@teneo.com)

 

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society
through enabling the analysis of anything, by anyone, anywhere. The company
has developed a new generation of nanopore-based sensing technology for
faster, information rich, accessible and affordable molecular analysis. The
first application is DNA/RNA sequencing, and the technology is in development
for the analysis of other types of molecules including proteins. The
technology is used in more than 125 countries to understand and characterise
the biology of humans and diseases such as cancer, plants, animals, bacteria,
viruses, and whole environments. Oxford Nanopore Technologies products are
intended for molecular biology applications and are not intended for
diagnostic purposes. For more, visit: www.nanoporetech.com
(http://www.nanoporetech.com/)

Forward-looking statements

This announcement contains certain forward-looking statements. For example,
statements regarding expected revenue growth and profit margins are
forward-looking statements. Phrases such as "aim", "plan", "expect", "intend",
"anticipate", "believe", "estimate", "target", and similar expressions of a
future or forward-looking nature should also be considered forward-looking
statements. Forward-looking statements address our expected future business
and financial performance and financial condition, and by definition address
matters that are, to different degrees, uncertain. Our results could be
affected by macroeconomic conditions, delays or challenges in manufacturing or
delivering of products to our customers, suspensions of large projects and/or
acceleration of large products or accelerated adoption of pathogen
surveillance or applied uses of our products. These or other uncertainties may
cause our actual future results to be materially different than those
expressed in our forward-looking statements.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFIFSEERILFIR



            Copyright 2019 Regulatory News Service, all rights reserved